These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8002094)

  • 21. In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies.
    Sader HS; Jones RN
    Eur J Clin Microbiol Infect Dis; 1994 Aug; 13(8):675-9. PubMed ID: 7813503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro antibacterial activities of FK037: a new parenteral cephalosporin.
    Inoue K; Inoue E; Mitsuhashi S
    Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The antimicrobial activity of cefpirome, a new cephalosporin.
    Wise R; Andrews JM; Cross C; Piddock LJ
    J Antimicrob Chemother; 1985 Apr; 15(4):449-56. PubMed ID: 3874198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro activity of cefpirome and other antimicrobial agents against isolates from cancer patients.
    Rolston K; Alvarez ME; Hoy JF; LeBlanc B; Ho DH; Bodey GP
    Chemotherapy; 1986; 32(4):344-51. PubMed ID: 3731920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of cefpirome (HR 810) against enterococci and staphylococci.
    Piacentini E; Amalfitano G; Ligozzi M; Canepari P; Fontana R
    J Chemother; 1992 Dec; 4(6):338-41. PubMed ID: 1287135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beta-lactamase stability and antibacterial activity of cefpirome alone and in combination with other antibiotics.
    Bakhtiar M; Selwyn S
    Drugs Exp Clin Res; 1989; 15(10):477-82. PubMed ID: 2698794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
    Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
    BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
    Tumah H
    Chemotherapy; 2005 May; 51(2-3):80-5. PubMed ID: 15870501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antibacterial activity of carumonam and cefpirome on hospital strains resistant to gentamicin and cephalothin: comparison with other beta-lactam antibiotics, new fluoroquinolones, aminoglycosides and other antibiotics].
    Vanhoof R; Nyssen HJ; Nulens E; Roebben E; Hubrechts JM
    Pathol Biol (Paris); 1990 Jun; 38(6):634-7. PubMed ID: 2165238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
    Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
    Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibilities of Chryseobacterium indologenes and Chryseobacterium meningosepticum to cefepime and cefpirome.
    Hsueh PR; Teng LJ; Yang PC; Ho SW; Luh KT
    J Clin Microbiol; 1997 Dec; 35(12):3323-4. PubMed ID: 9399547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of cefpirome (HR810) against Pseudomonas aeruginosa strains with characterised resistance mechanisms to beta-lactam antibiotics.
    Gargalianos P; Oppenheim BA; Skepastianos P; Livermore DM; Williams RJ
    J Antimicrob Chemother; 1988 Dec; 22(6):841-8. PubMed ID: 3149631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.
    Dobias J; Dénervaud-Tendon V; Poirel L; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2319-2327. PubMed ID: 28748397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibility of non-fermentative gram-negative bacteria to ciprofloxacin, norfloxacin, amifloxacin, pefloxacin and cefpirome.
    Appelbaum PC; Spangler SK; Sollenberger L
    J Antimicrob Chemother; 1986 Dec; 18(6):675-9. PubMed ID: 3469178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ; Sader HS; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.